RT Journal Article
T1 Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.
A1 Soria-Juan, Bárbara
A1 Escacena, Natalia
A1 Capilla-González, Vivian
A1 Aguilera, Yolanda
A1 Llanos, Lucía
A1 Tejedo, Juan R
A1 Bedoya, Francisco J
A1 Juan, Verónica
A1 De la Cuesta, Antonio
A1 Ruiz-Salmerón, Rafael
A1 Andreu, Enrique
A1 Grochowicz, Lukas
A1 Prósper, Felipe
A1 Sánchez-Guijo, Fermín
A1 Lozano, Francisco S
A1 Miralles, Manuel
A1 Del Río-Solá, Lourdes
A1 Castellanos, Gregorio
A1 Moraleda, José M
A1 Sackstein, Robert
A1 García-Arranz, Mariano
A1 García-Olmo, Damián
A1 Martín, Franz
A1 Hmadcha, Abdelkrim
A1 Soria, Bernat
A1 Collaborative Working Group “Noma Project Team”, 
K1 cell-based therapy
K1 cellular medicaments
K1 clinical trials
K1 cost-effective
K1 critical limb ischemia
K1 diabetes
AB [This corrects the article DOI: 10.3389/fimmu.2019.01151.].
YR 2020
FD 2020-09-02
LK http://hdl.handle.net/10668/16331
UL http://hdl.handle.net/10668/16331
LA en
DS RISalud
RD Apr 11, 2025